Lexicon Pharmaceuticals LXRX Debt Issuance Cost Amortization
Debt Issuance Cost Amortization at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCostsAndDiscounts.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's debt issuance cost amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's debt issuance cost amortization?
- Lexicon Pharmaceuticals (LXRX) reported debt issuance cost amortization of $681K in Q1 2026.
- How has Lexicon Pharmaceuticals's debt issuance cost amortization changed year-over-year?
- Lexicon Pharmaceuticals's debt issuance cost amortization increased by 69.8% year-over-year, from $401K to $681K.
- What is the long-term trend for Lexicon Pharmaceuticals's debt issuance cost amortization?
- Over 4 years (2021 to 2025), Lexicon Pharmaceuticals's debt issuance cost amortization has grown at a 136.9% compound annual growth rate (CAGR), from $54K to $1.7M.
- What does debt issuance cost amortization mean?
- Non-cash amortization of capitalized costs incurred to issue debt (underwriting fees, legal costs, SEC filing fees).